![](https://d3ilqtpdwi981i.cloudfront.net/Rm5MXjzlI9vfU7cBzuPa1HIe7FE=/425x550/smart/https://bepress-attached-resources.s3.amazonaws.com/uploads/86/15/8a/86158a17-e8b7-4c79-859d-f2e11bf9cbe0/thumbnail_691de973-e287-41d1-987d-5dfbc4da780e.jpg)
The biological determinants of the wide spectrum of COVID-19 clinical manifestations are not fully understood. Here, over 1400 plasma proteins and 2600 single-cell immune features comprising cell phenotype, basal signaling activity, and signaling responses to inflammatory ligands were assessed in peripheral blood from patients with mild, moderate, and severe COVID-19, at the time of diagnosis. Using an integrated computational approach to analyze the combined plasma and single-cell proteomic data, we identified and independently validated a multivariate model classifying COVID-19 severity (multi-class AUCtraining = 0.799, p-value = 4.2e-6; multi-class AUCvalidation = 0.773, p-value = 7.7e-6). Features of this high-dimensional model recapitulated recent COVID-19 related observations of immune perturbations, and revealed novel biological signatures of severity, including the mobilization of elements of the renin-angiotensin system and primary hemostasis, as well as dysregulation of JAK/STAT, MAPK/mTOR, and NF-κB immune signaling networks. These results provide a set of early determinants of COVID-19 severity that may point to therapeutic targets for the prevention of COVID-19 progression.
Available at: http://works.bepress.com/xiaoyuan-han/54/
This is an unpublished pre-print that has not undergone peer review. It should not be considered conclusive, used to inform clinical practice, or referenced by the media as validated information.